Test Catalog

Test ID: CVRMP    
Cardiovascular Risk Marker Panel, Serum

Useful For Suggests clinical disorders or settings where the test may be helpful

Assessment for risk of developing cardiovascular disease, major adverse cardiovascular events, or ischemic cerebrovascular events

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Cardiovascular disease is the number 1 cause of death in the United States with an estimated 1.5 million heart attacks and 0.5 million strokes occurring annually. Many of these events occur in individuals who have no prior symptoms. Standard risk factors, including age, smoking status, hypertension, diabetes, cholesterol, and HDL cholesterol, predict only about 65% of individuals who will go on to have a cardiovascular event. Therefore, identification of patients with residual risk is important to target lifestyle and pharmaceutical intervention to those at higher risk of future events.


Many additional risk markers have been identified for cardiovascular disease but few have emerged as independent risk markers. Two of these additional risk markers, high-sensitivity C-reactive protein (hsCRP) and lipoprotein (a) (Lp[a]), are clearly shown to be independently associated with increased risk of future cardiovascular events. Several recent guidelines have suggested that clinicians utilize hsCRP and Lp(a) in selected persons to augment risk classification, guide intensity of risk-reduction therapy and modulate clinical judgment when making therapeutic decision.(1-3) Prospective studies assessing these risk factors individually have determined them to be independently associated with increased risk for the development of ischemic events.


Guidelines recommend measurement of additional risk markers in individuals who are at intermediate risk for developing cardiovascular disease, those with early atherosclerosis without explanation by abnormalities of traditional risk factors, and those with a strong family history of cardiovascular disease without the presence of traditional risk factors.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

Reference values apply to fasting specimens only.



2-17 years

>18 years

Non-HDL Cholesterol (mg/dL)


Acceptable: <120

Borderline high: 120-144

High: > or =145


Desirable: <130 mg/dL

Above Desirable: 130-159 mg/dL

Borderline high: 160-189 mg/dL

High: 190-219 mg/dL

Very high: > or =220 mg/dL

LDL Cholesterol (mg/dL)


Acceptable: <110

Borderline high: 110-129

High: > or =130


Desirable: <100

Above Desirable: 100-129

Borderline high: 130-159

High: 160-189

Very high: > or =190

HDL Cholesterol (mg/dL)


Low: <40

Borderline low: 40-45

Acceptable: > 45


Males: > or =40

Females: > or =50


Total Cholesterol (mg/dL)


Acceptable: <170

Borderline high: 170-199

High: > or =200


Desirable: < 200

Borderline high: 200 - 239

High: > or = 240


< or =30 mg/dL

Values >30 mg/dL may suggest increased risk of coronary heart disease.

< or =30 mg/dL

Values >30 mg/dL may suggest increased risk of coronary heart disease.



Lower risk: <2.0 mg/L

Higher risk: >=2.0 mg/L

Acute inflammation: >10.0 mg/L


Lower risk: <2.0 mg/L

Higher risk: >=2.0 mg/L

Acute inflammation: >10.0 mg/L



2-9 years

10-17 years

>18 years

Triglycerides (mg/dL)


Acceptable: <75 

Borderline high: 75-99

High: > or =100


Acceptable: <90 

Borderline high: 90-129

High: > or =130


Normal: <150

Borderline high: 150-199

High: 200-499

Very high: > or =500


*National Lipid Association 2014

**Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents

***National Cholesterol Education Program (NCEP)

Interpretation Provides information to assist in interpretation of the test results

Specific interpretations are provided based on lipid results according to Mayo Clinic care process models. Mayo Clinic has adopted the National Lipid Association classifications, which are included as reference values on Mayo Clinic and Mayo Clinic Laboratories reports (see Reference Values).


More aggressive treatment strategies may be pursued in patients determined to be at increased risk.


See Lipids and Lipoproteins in Blood Plasma (Serum) in Special Instructions.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Lipid values should be considered in the context of clinical presentation. Additional risk factors include cigarette smoking, hypertension, age and personal or family history of cardiovascular disease.


Result can be falsely decreased in patients with elevated levels of N-acetyl-p-benzoquinone imine (NAPQI)-a metabolite of acetaminophen, N-acetylcysteine (NAC), and metamizole.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Jacobson TA, Ito MK, Maki KC, et al: National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol 2014 Sep-Oct;8(5):473-488

2. Perk J, DeBacker G, Gohlke H, et al: European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2012;33:1635-1701

3. Goff DC, Lloyd-Jones DM, Gennett G, et al: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation 2014;129:S49-S73

4. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute: Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Pediatrics 2011;128;S213-S256

5. Ridker PM, Rifai N, Rose L, et al: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002 Nov 14;347(20):1557-1565

6. Ridker PM, Danielson E, Fonseca FA, et al: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175–1182

Special Instructions Library of PDFs including pertinent information and forms related to the test